Disc Medicine director Mona Ashiya resigns from board

Disc Medicine, Inc. reported that board member Mona Ashiya, Ph.D., a Class I director, resigned from its Board of Directors effective October 3, 2025.

Rhea-AI Filing Summary

Disc Medicine, Inc. reported that board member Mona Ashiya, Ph.D., a Class I director, resigned from its Board of Directors effective October 3, 2025. She also stepped down from the Board’s Compensation Committee and Nominating and Corporate Governance Committee. The company stated that her resignation was not due to any disagreement with Disc Medicine regarding its operations, policies, or practices. Following her departure, the size of the Board was reduced from nine members to eight.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Disc Medicine, Inc. (IRON) announce in this 8-K filing?

Disc Medicine, Inc. disclosed that Mona Ashiya, Ph.D., a Class I member of its Board of Directors, resigned effective October 3, 2025, and the Board size was reduced from nine to eight members.

Why did Mona Ashiya, Ph.D. resign from the Disc Medicine (IRON) board?

The company stated that Dr. Ashiya’s decision to resign was not the result of any disagreement with Disc Medicine on matters relating to its operations, policies, or practices.

What board committees did Mona Ashiya serve on at Disc Medicine (IRON)?

Mona Ashiya, Ph.D. served on the Compensation Committee and the Nominating and Corporate Governance Committee of the Board before her resignation.

How did the Disc Medicine (IRON) board size change after the resignation?

Effective upon Dr. Ashiya’s resignation on October 3, 2025, the size of Disc Medicine’s Board of Directors was reduced from nine members to eight.

Does Disc Medicine (IRON) report any disagreement with the departing director?

No. Disc Medicine explicitly stated that Dr. Ashiya’s resignation was not due to any disagreement regarding the company’s operations, policies, or practices.

Who signed the Disc Medicine (IRON) 8-K reporting the board resignation?

The report was signed on behalf of Disc Medicine, Inc. by John Quisel, J.D., Ph.D., the company’s Chief Executive Officer, dated October 6, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 04:20 PM EDT Learn about SEC filing dates

0001816736false00018167362025-10-032025-10-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 03, 2025

DISC MEDICINE, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39438	85-1612845
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
321 Arsenal Street Suite 101
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 674-9274

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		IRON		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 3, 2025, Mona Ashiya, Ph.D., a Class I member of the Board of Directors (the “Board”) of Disc Medicine, Inc. (the “Company”), notified the Company of her resignation from the Board, effective October 3, 2025. Dr. Ashiya was a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board and, by resigning from the Board, also resigned from such committees.

Dr. Ashiya's decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Effective upon Dr. Ashiya’s resignation, the size of the Board was reduced from nine members to eight.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			DISC MEDICINE, INC.
Date:	October 6, 2025	By:	/s/ John Quisel, J.D., Ph.D.
			John Quisel, J.D., Ph.D. Chief Executive Officer